Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists. - Wikidata - wikimedia - TriplyDB

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

http://www.wikidata.org/entity/Q33593241

about

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System

P2860

Q26999386-226A1655-15FB-4398-9F45-0993BEB041FB

P2860

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

http://www.wikidata.org/entity/Q33593241

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

@ast

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

@en

type

label

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

@ast

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

@en

prefLabel

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

@ast

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

@en

P1433

Q33593241-D3B4583E-C23D-486C-9B7B-CDD06535E72B

P1476

Q33593241-C0267328-BCCF-4CA6-B705-46809AEFC677

P2093

Q33593241-638FA7F4-D942-4006-9871-FB0397F42F9A

Q33593241-CEA1B48F-55AC-4DA6-8A7C-B9F8ACCFF634

Q33593241-D099813E-C49A-409A-8AE7-53559FDF987D

Q33593241-FD35E4A6-3FB1-4ECC-9EDF-0991A8886B4E

P2860

Q33593241-41C532E7-1590-4832-90AD-CD1DA907301A

Q33593241-48406E11-7485-4B25-8F03-B5DB59F36042

Q33593241-4859A218-FE57-46A0-A113-B213039DB79F

Q33593241-4F8E6F13-BC02-415B-A12B-DF7A65FB18F7

Q33593241-60BCF094-A0F6-4935-B1D6-8E5858913BBF

Q33593241-72F4C38B-442A-436E-9A76-F9B824399911

Q33593241-85B6006E-1211-4ED1-A899-BAC11F4026D4

Q33593241-94D33A4A-A26F-4B79-AD5E-AACB71620E48

Q33593241-AD1415DB-EC3D-40F2-B0CC-4DF8FFACA02C

Q33593241-CD83553F-B34F-4AAD-BA35-2B7315D195D8

P2888

Q33593241-07406812-7E27-49BE-A304-C62D532B50FE

P304

Q33593241-52E4E5FF-A60D-46AF-82C4-40391E8F0C24

P31

Q33593241-491CA3D5-D8AC-419C-B8A6-508CFAFE65C7

P356

Q33593241-954B96B6-6204-4851-8A7A-F74DF5D2D96A

P433

Q33593241-693BF35F-B395-4D85-875F-ADC8E3FFBEDC

P478

Q33593241-FC4CD0FC-6B3E-464E-9BCD-3BF8CF53F56B

P50

Q33593241-EAFED0F7-A101-4D54-862D-4B03F3CD0FAD

P577

Q33593241-0A61517B-AFF5-4B6F-A3F6-AA1C37C060AF

P5875

Q33593241-C7145397-B32C-4E7E-AF5E-E763091F7EA7

P6179

Q33593241-2862D0A0-CDB9-49C8-AEE4-2C2C01363AEB

P698

Q33593241-25CB58B2-AE76-4467-B047-2186B0483616

P932

Q33593241-B49BF4DF-1CA7-48AC-9612-35263C6754BE

P356

S12272-013-0253-9

P1433

Archives of Pharmacal Research

P1476

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.

@en

P2093

Hyae-Gyeong Cheon

http://www.w3.org/2001/XMLSchema#string

Jin-Hyun Jeong

http://www.w3.org/2001/XMLSchema#string

Liu-Lan Shen

http://www.w3.org/2001/XMLSchema#string

Yu-Juan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs

Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy

Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes?

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?

Insulin therapy and its shortcomings - the need for new approaches.

Identification of aryl 2-aminoimidazoles as biofilm inhibitors in Gram-negative bacteria.

Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization.

Where are we now in diabetic research?

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

P2888

s12272-013-0253-9

P304

588-599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12272-013-0253-9

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258215397

http://www.w3.org/2001/XMLSchema#string

P6179

1029307949

http://www.w3.org/2001/XMLSchema#string

P698

24178744

http://www.w3.org/2001/XMLSchema#string

P932

4016675

http://www.w3.org/2001/XMLSchema#string